Flare Therapeutics Inc. has closed an $85 million series C financing and completed a strategic review of its pipeline, with funds being channeled to advance the prioritized programs.
Prostate cancer is a leading cause of cancer-related deaths among men and is a cancer type that shows genomic heterogeneity and several molecular alterations. By analyzing available microarray and next-generation transcriptome sequencing data, researchers at the University of Alabama at Birmingham found that thyroid hormone receptor-interacting protein 13 (TRIP13), a member of the AAA ATPase family, was overexpressed in prostate cancer, making it a potential therapeutic target.
Uniquest Pty Ltd., the commercialization company of the University of Queensland, has entered into an exclusive license agreement with the Ellison Medical Institute (EMI) to develop and commercialize the University of Queensland’s QED-203 for metastatic castration-resistant prostate cancer.
Shanghai Henlius Biotech Inc.’s HLX-3902, a trispecific antibody targeting STEAP1xCD3xCD28, has received approval from the Human Research Ethics Committee (HREC) in Australia and has been filed with the Therapeutic Goods Administration (TGA). The T-cell engager is intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors.
Resistance to microtubule-targeting agents such as taxanes and vinca alkaloids is often driven by drug efflux and changes in tubulin behavior. Targeting the colchicine-binding site provides an alternative strategy that may circumvent these resistance mechanisms.
Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor (ARON) degrader, in models of prostate cancer.
T-cell engagers (TCEs) drive synthetic antitumor immunity by bypassing endogenous T-cell priming and directly inducing tumor cell killing. In prostate cancer, targeting prostate-restricted antigens such as STEAP2, combined with CD8-guided TCE formats that favor cytotoxic T-cell engagement, offers a strategy to reduce cytokine release while maintaining antitumor activity.
After a hiatus of more than nine months, the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) will meet April 30 to discuss two Astrazeneca plc applications – an NDA for camizestrant used in combination with a CDK4/6 inhibitor to treat HR+HER2- locally advanced or metastatic breast cancer and an sNDA for Truqap (capivasertib) to treat metastatic hormone-sensitive prostate cancer that’s phosphatase and tensin homolog deficient.
U.S. researchers have published data regarding IVMT-Rx-4, a melanoma differentiation-associated gene-9 (MDA-9) inhibitor with potential to treat bone-metastatic prostate cancer.
Retinoid X receptor γ (RXRγ) is a key nuclear receptor that sustains androgen receptor (AR) signaling. In castration-resistant prostate cancer (CRPC), RXRγ contributes to disease progression by maintaining adaptive transcriptional networks that promote therapy resistance and tumor cell survival.
